...on the HSV and adenovirus backbones. Companies with HSV therapies include Replimune, Oncorus Inc. and Virogen...

...compounds in mouse models of type 2 diabetes. Celgosivir (MX-3253), an a-glucosidase I inhibitor from Virogen Ltd....
...II testing to treat chronic HCV infection. Migenix Inc. has global rights to celgosivir from Virogen...

...the trial next quarter. Migenix acquired global rights to the alpha glucosidase I inhibitor from Virogen Ltd....

...acquired global rights to celgosivir from Virogen in 2004. Migenix Inc. (TSX:MGI; Pink:MGIFF), Vancouver, B.C. Virogen Ltd....

...MBI acquired global rights to Virogen's celgosivir, an oral antiviral in Phase I/II testing to treat...
...I/II testing to treat chronic HCV. MBI plans to start Phase II testing this year. Virogen...
...equity, and is eligible for milestones and royalties. Micrologix Biotech Inc. (TSE:MBI; MGIXF), Vancouver, B.C. Virogen Ltd....

...inhibitor that has completed Phase I/II testing to treat viral hepatitis (see BioCentury, Jan. 22). Virogen Ltd....

...interested in working on viruses. In essence, according to Stan Tyms, president and CEO of Virogen...
...from tech transfer toward incubation of new companies and the result was the formation of Virogen...
...own. Virogen also hopes to expand its in-house glycoprotein processing expertise by adding medicinal chemistry. Virogen's...

...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...
...fund its own development costs, and revenues will be shared. Arrow Therapeutics Ltd., London, U.K. Virogen Ltd....

...Arrow Therapeutics (London, U.K.) and Virogen (London, U.K.) will develop therapeutics to treat respiratory syncytial virus...
...develop therapeutics to treat respiratory syncytial virus (RSV). Arrow will provide its compound library to Virogen...